Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02998554 · ClinicalTrials.gov registry record · Phase 3
Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo
A Phase 3 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 156
- Enrollment target
NCT02998554: Clinical Trial Phase 3 study, sponsored by Shire.
NCT02998554 is a Phase 3 study that was terminated before completion, run by Shire. The registered enrollment target is 156 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02998554, a Phase 3 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 156 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if an investigational treatment is effective compared with placebo in the treatment of adults and children with adenoviral conjunctivitis.
Primary Outcome
Clinical resolution of adenoviral conjunctivitis was defined as the absence (score = 0) of bulbar conjunctival injection and watery conjunctival discharge in the study eye. Bulbar conjunctival injection was assessed based on a 0 (Normal conjunctival vascular pattern)-4 (Markedly prominent, intense diffuse hyperemia) scale which used pictures from the validated bulbar redness (VBR) scale. Watery conjunctival discharge was assessed based on a 0-3 scale (0 - None and 3 - Severe: Abundant quantity o
Interventions
- DRUG Placebo
- DRUG SHP640
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2017-03-28 |
| Est. Completion | 2019-05-16 |
| Phase | Phase 3 |
Why NCT02998554 stopped before completion
NCT02998554 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02998554 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02998554 about?
NCT02998554 is a clinical study titled "Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo". The purpose of this study is to determine if an investigational treatment is effective compared with placebo in the treatment of adults and children with adenoviral conjunctivitis.
What is the current status of trial NCT02998554?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 156 participants. The study started on 2017-03-28. Estimated completion is 2019-05-16.
What interventions are being tested in trial NCT02998554?
The interventions under investigation include: Placebo (DRUG), SHP640 (DRUG).
Who is sponsoring clinical trial NCT02998554?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02998554's enrollment target sits among peer trials
156 1506th of 2000 higher than 492 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI